Trial Profile

A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Nov 2017 According to a Gemphire Therapeutics media release, company presented the data at the American Heart Associations (AHA) Scientific Sessions in Anaheim, California on November 2017 showing that gemcabene significantly reduces atherogenic remnant lipoprotein and LDL-C as add-on to statins in a cardiometabolic population.
13 Nov 2017 Results published in the Gemphire Therapeutics Media Release.
11 Nov 2017 Trial design and other study details presented at the 90th Annual Scientific Sessions of the American Heart Association.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com